fast biopharma

Designing a drug development program for the ‘20s

A combination of new technology and regulatory reform has made it possible to fundamentally change the speed of drug development, which may have profound implications in pricing and ROI. This covers everything from discovery to trial design, manufacturing and fast-tracking talks with regulators.

We’ll bring together some of the industry’s top drug developers to talk about the new standard for development — and what that means for biopharma in the ‘20s.

june 9th 2020
6:30 - 8:45am
omni san diego hotel
675 L Street, San Diego, CA 92101

Early Bird Rate (until May 19) - $175
General Admission (May 19 - June 8) - $195
Endpoints Premium Subscribers - $100 flat rate - SUBSCRIBE NOW!

panelists

Andrew Plump

Andrew Plump

President, Research and Development
Takeda
David Reese

David Reese

Executive Vice President, Research and Development
Amgen
John Carroll

John Carrollmoderator

Founder & Editor
Endpoints News

previous endpoints events